A Study to Compare the Efficacy and Safety of Different Doses of Ivermectin for COVID-19

Inclusion Criteria: * Diagnosis of infection by SARS-CoV-2: 1. symptoms of acute respiratory tract infection (sudden onset of at least one of the following: cough, fever, shortness of breath) and biomolecular diagnosis of SARS-CoV-2 infection; OR 2. any acute respiratory disease AND biomolecular diagnosis of SARS-CoV-2 infection; OR 3. severe acute respiratory infection (fever and at least one sign / symptom of respiratory disease eg cough, fever, shortness of breath) AND in need of hospitalization AND biomolecular diagnosis of SARS-CoV-2 infection; * Eastern Cooperative Oncology Group Performance Status score 0 to 1; * National Early Warning Score 0 to 4; * Ability to understand and consent to participate in this clinical trial, manifested by signing the Informed Consent Form (ICF). Exclusion Criteria: * Inability to ingest / absorb the study drug orally through spontaneous ingestion or use of gastro / enteral tubes; * Any finding of clinical observation (history / physical evaluation) that is interpreted by the investigating physician as a risk to participate in the trial; * Any laboratory test findings that the investigating physician considers as a risk to the research participant as to his / her participation in the clinical study; * Any ECG examination finding that the investigating physician considers as a risk to the research participant as to his / her participation in the trial; * Known hypersensitivity to the components of the drugs used during the study; * Women in pregnancy or breastfeeding; * Body weight less than 15kg; * Estimated glomerular filtration rate (CKD-Epidemiology Collaboration, CKD-EPI) \<30 mL / min; * Aspartate aminotransaminase (AST) or alanine aminotransaminase (ALT)\> 5 times the upper limit of normality; * Refusal to participate; * Refusal to sign the informed consent form.